Vancouver, British Columbia – September 11, 2015 – Sirona Biochem Corp. (TSX-V: SBM) (Frankfurt: ZSB), (the “Company”) is pleased to announce that the Company’s shares have been accepted for continuous trading on the German electronic trading platform Xetra® under the ticker symbol “ZSB.DE”. The International Security Identification Number (ISIN) is CA82967M1005.
The electronic trading system Xetra® is utilized to trade approximately 300,000 international instruments. Xetra® has a market share of over 90 percent in equity trading and is one of the fastest trading systems in the world with a round-trip-time at only two milliseconds. Financial institutions, securities trading houses and brokers can participate in Xetra® trading. Xetra® operates independently of the trader’s location, permitting international participation. In fact, more than 130 participants from European countries outside Germany trade on Xetra®.
Sirona Biochem has appointed Hauck & Aufhäuser Privatbankiers KGaA (H&A) as its designated sponsor on Xetra®. The designated sponsor will work to facilitate higher liquidity in stock trading of Sirona common shares by maintaining a constant quotation volume (minimum trade volume) to ensure tradability is guaranteed – even in highly volatile market periods.
Dr. Howard Verrico, CEO and Chairman of Sirona Biochem, stated, “The Xetra® listing marks a further step in Sirona’s commitment to its shareholders to enhance the liquidity of the Company’s common shares and is one of many initiatives we are taking to further increase market awareness. A generally visible valuation discount due to limited liquidity will be reduced and therefore should generate an increased interest of institutional investors. Several potential European investors have confirmed that a continuous Xetra® listing will make it easier for them to invest in Sirona. We are proud that, from our point of view, the best Xetra® specialist team in Germany has chosen Sirona as a new client.”
About Hauck & Aufhäuser Privatbankiers KGaA
Hauck & Aufhäuser Privatbankiers is one of the few independent private banks in Germany and can look back on over 219 years of tradition. The bank resulted from the 1998 merger of two highly traditional private banks: Georg Hauck & Sohn Bankiers, founded in Frankfurt am Main in 1796, and Bankhaus H. Aufhäuser, which opened its doors in Munich in 1870.
From its locations in Frankfurt am Main, Munich, Hamburg, Düsseldorf and Cologne, the bank focuses on providing comprehensive advisory services and administering the assets of its private, corporate and institutional clients. This includes asset management for institutional investors, close cooperation with independent asset managers and both the concept and management of private label funds.
The partners of the bank consist of the personally liable partner, Jochen Lucht, and the partners, Michael O. Bentlage and Stephan Rupprecht. All of the bank’s capital is in the hands of private investors. Hauck & Aufhäuser considers itself a private bank that combines modernity with a strong sense of tradition. The focus of its business activities is on providing comprehensive and personalized advisory services, which form the basis for developing customized solutions. For more information visit: www.hauck-aufhaeuser.de.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The Company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds’ efficacy and safety. Sirona Biochem’s compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem’s wholly-owned French laboratory, is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit: www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information regarding this press release, contact:
Christopher Hopton, CFO
Sirona Biochem Corp.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.